Effect of paclitaxel in gefitinib-resistant non-small cell lung cancer (NSCLC) treatment during the COVID-19 pandemic.

被引：0
|
作者：
Mohiuddin, Md [1 ]
Kasahara, Kazuo [1 ]
机构：
[1] Kanazawa Univ, Dept Resp Med, Kanazawa, Ishikawa, Japan
来源：
CLINICAL CANCER RESEARCH | 2020年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P27
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Continued implications of the COVID-19 pandemic environment on non-small cell lung cancer characteristics and treatment in the United States
    Stuart, Christina M.
    Mott, Nicole M.
    Bronsert, Michael R.
    Dyas, Adam R.
    Franco, Salvador Rodriguez
    Gleisner, Ana L.
    Randhawa, Simran K.
    David, Elizabeth A.
    Mitchell, John D.
    Meguid, Robert A.
    JOURNAL OF THORACIC DISEASE, 2025, 17 (01)
  • [42] Impact of COVID-19 Pandemic on Proportion and Treatment Patterns for Stage I Non-small Cell Lung Cancer in the Netherlands
    Wolfhagen, N.
    Smit, H. J.
    Schuurbiers, O. C.
    Belderbos, J. S. A.
    Verhagen, A. F. T. M.
    Schreurs, H. W. H.
    Damhuis, R. A.
    Heineman, D. J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S18 - S19
  • [43] The results of the treatment with gefitinib (Iressa) in 89 patients with advanced non-small cell lung cancer (NSCLC)
    Skrickova, J
    Tomiskova, M
    Svobodnik, A
    Kaplanova, J
    Kadlec, B
    Palkova, I
    Babickova, L
    Stratil, D
    Nebesky, T
    LUNG CANCER, 2005, 49 : S376 - S376
  • [44] Gefitinib and Afatinib Treatment in an Advanced Non-small Cell Lung Cancer (NSCLC) Patient Undergoing Hemodialysis
    Bersanelli, Melissa
    Tiseo, Marcello
    Artioli, Fabrizio
    Lucchi, Leonardo
    Ardizzoni, Andrea
    ANTICANCER RESEARCH, 2014, 34 (06) : 3185 - 3188
  • [45] Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway
    Li, Xia
    Fan, Xing-Xing
    Jiang, Ze-Bo
    Loo, Wings T. Y.
    Yao, Xiao-Jun
    Leung, Elaine Lai-Han
    Chow, Louis W. C.
    Liu, Liang
    PHARMACOLOGICAL RESEARCH, 2017, 115 : 45 - 55
  • [46] Chemical Synthesis of Novel DDR1 Inhibitors and Their Activity Against Gefitinib-Resistant Non-Small Cell Lung Cancer
    Xu, Xuemei
    Chen, Siyu
    Sun, Doudou
    Wang, Xuebao
    Xu, Zhouyang
    RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY, 2025, 51 (01) : 285 - 297
  • [47] Erlotinib response EGFR-mutant gefitinib-resistant non-small-cell lung cancer
    Chang, John Wen-Cheng
    Chou, Chun-Liang
    Huang, Shiu-Feng
    Wang, Hung-Ming
    Hsieh, Jia-Juan
    Hsu, Todd
    Cheung, Yun-Chung
    LUNG CANCER, 2007, 58 (03) : 414 - 417
  • [48] Role of gefitinib (G) in heavily pretreated non-small cell lung cancer (NSCLC)
    Tamburini, E.
    Tassinari, D.
    Pasquini, E.
    Papi, M.
    Possenti, C.
    Drudi, F.
    Castellani, C.
    Santelmo, C.
    Carloni, F.
    Ravaioli, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [49] Serum EGFR in patients with non-small cell lung cancer (NSCLC) treated with gefitinib
    Spreafico, A
    Gregorc, V
    Ludovini, V
    Pistola, L
    Amoroso, M
    Tofanetti, F
    Compagnoni, A
    Aondio, G
    Tonato, M
    Villa, E
    LUNG CANCER, 2005, 49 : S112 - S113
  • [50] Gefitinib and celecoxib in patients with platinum refractory non-small cell lung cancer (NSCLC).
    Gadgeel, SM
    Shehadeh, NJ
    Ruckdeschel, JC
    Chaplen, RA
    Belzer, K
    Wozniak, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 639S - 639S
12345